RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      Korean Guidelines for the Diagnosis and Management of Dry Eye: Development and Validation of Clinical Efficacy

      한글로보기

      https://www.riss.kr/link?id=A103855928

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose: To evaluate the clinical efficacy of newly developed guidelines for the diagnosis and management ofdry eye. Methods: This retrospective, multi-center, non-randomized, observational study included a total of 1,612 patientswith dry eye disease ...

      Purpose: To evaluate the clinical efficacy of newly developed guidelines for the diagnosis and management ofdry eye.
      Methods: This retrospective, multi-center, non-randomized, observational study included a total of 1,612 patientswith dry eye disease who initially visited the clinics from March 2010 to August 2010. Korean guidelinesfor the diagnosis and management of dry eye were newly developed from concise, expert-consensus recommendations.
      Severity levels at initial and final visits were determined using the guidelines in patients with 90± 7 days of follow-up visits (n = 526). Groups with different clinical outcomes were compared with respect toclinical parameters, treatment modalities, and guideline compliance. Main outcome measures were ocular andvisual symptoms, ocular surface disease index, global assessment by patient and physician, tear film break-uptime, Schirmer-1 test score, ocular surface staining score at initial and final visits, clinical outcome after threemonths of treatment, and guideline compliance.
      Results: Severity level was reduced in 47.37% of patients treated as recommended by the guidelines. Youngerage (odd ratio [OR], 0.984; p = 0.044), higher severity level at initial visit, compliance to treatment recommendation(OR, 1.832; p = 0.047), and use of topical cyclosporine (OR, 1.838; p = 0.011) were significantly associatedwith improved clinical outcomes.
      Conclusions: Korean guidelines for the diagnosis and management of dry eye can be used as a valid and effectivetool for the treatment of dry eye disease.

      더보기

      참고문헌 (Reference)

      1 Sall K, "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group" 107 : 631-639, 2000

      2 Nichols KK, "The lack of association between signs and symptoms in patients with dry eye disease" 23 : 762-770, 2004

      3 Nelson JD, "The international workshop on meibomian gland dysfunction:report of the definition and classification subcommittee" 52 : 1930-1937, 2011

      4 "The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Work-Shop (2007)" 5 : 93-107, 2007

      5 "The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)" 5 : 75-92, 2007

      6 Lemp MA, "Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes" 21 : 221-232, 1995

      7 Schiffman RM, "Reliability and validity of the Ocular Surface Disease Index" 118 : 615-621, 2000

      8 Han SB, "Prevalence of dry eye disease in an elderly Korean population" 129 : 633-638, 2011

      9 Barber LD, "Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years" 112 : 1790-1794, 2005

      10 "Methodologies to diagnose and monitor dry eye disease:report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007)" 5 : 108-152, 2007

      1 Sall K, "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group" 107 : 631-639, 2000

      2 Nichols KK, "The lack of association between signs and symptoms in patients with dry eye disease" 23 : 762-770, 2004

      3 Nelson JD, "The international workshop on meibomian gland dysfunction:report of the definition and classification subcommittee" 52 : 1930-1937, 2011

      4 "The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Work-Shop (2007)" 5 : 93-107, 2007

      5 "The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)" 5 : 75-92, 2007

      6 Lemp MA, "Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes" 21 : 221-232, 1995

      7 Schiffman RM, "Reliability and validity of the Ocular Surface Disease Index" 118 : 615-621, 2000

      8 Han SB, "Prevalence of dry eye disease in an elderly Korean population" 129 : 633-638, 2011

      9 Barber LD, "Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years" 112 : 1790-1794, 2005

      10 "Methodologies to diagnose and monitor dry eye disease:report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007)" 5 : 108-152, 2007

      11 "Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)" 5 : 163-178, 2007

      12 Bron AJ, "Grading of corneal and conjunctival staining in the context of other dry eye tests" 22 : 640-650, 2003

      13 Perry HD, "Evaluation of topical cyclosporine for the treatment of dry eye disease" 126 : 1046-1050, 2008

      14 Behrens A, "Dysfunctional tear syndrome:a Delphi approach to treatment recommendations" 25 : 900-907, 2006

      15 Nichols KK, "Association of clinical diagnostic tests and dry eye surveys: the NEI-VFQ-25 and the OSDI" 506 (506): 1177-1181, 2002

      16 Wilson SE, "Agreement of physician treatment practices with the international task force guidelines for diagnosis and treatment of dry eye disease" 26 : 284-289, 2007

      17 Baiza-Duran L, "A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome" 94 : 1312-1315, 2010

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2020-01-01 평가 등재학술지 선정 (재인증) KCI등재
      2019-12-01 평가 등재후보로 하락 (계속평가) KCI등재후보
      2010-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2009-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2007-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.11 0.11 0.12
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.1 0.13 0.482 0.03
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼